Indian biotech R & D has made significant advances in multiple sectors including pharma where we have built sustained capabilities towards developing drugs , not just generics but including novel drugs , biologics and now biopharma .
We have made huge strides in medical devices where we are seeing indigenous development of world-class technologies . I have faith that going forward this sector in healthtech will have great outcomes in making high quality medical devices affordable and accessible by all .
“
A push incentive for innovation now will help consolidate the huge gains we have made nationwide in R & D during the pandemic .
Agriculture biotech is the third area where Indian technology is at the global cutting-edge . We have several such examples . The most recent one of GMO Mustard seed that has received regulatory approval demonstrates the coming of age of agri biotech . The fourth development that I need to pick out is the quantum leap in R & D capabilities both in industry and academia which augurs well for the future of S & T in India in terms of social , financial and economic dividends going forward .
Do you agree that our attitude towards R & D during the pandemic has witnessed significant acceleration ? What is different now ?
I completely agree that there has been significant change in the public outlook of R & D since the pandemic . Across the world , science is now publicly regarded as a crucial tool to build solutions for larger good . The pandemic created a massive push for innovation in solutions .
BIOVOICENEWS . COM 23